¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Calcium Channel Blocking Agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® calcium ÇÑ±Û Ä®½·
¼³¸í   
  ½ÅüÀÇ °ÅÀÇ ¸ðµç Á¶Á÷¿¡¼­ ¹ß°ßµÇ´Â ÀüÇØÁú·Î ¿©·¯ °¡Áö ¿ªÇÒÀ» ¸ö¿¡¼­ ´ã´çÇÑ´Ù. Áß¿äÇÑ ±â´ÉÀ» »ìÆìº¸¸é ¿ì¼± Àλê°ú °áÇÕÇÏ¿© »À³ª ÀÌ»¡À» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù. ±×¸®°í ¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡ ¾ø¾î¼­´Â ¾ÈµÉ ÀüÇØÁú·Î ÀÛ¿ëÀ» ÇÑ´Ù. Ç÷¾×ÀÀ°íÀÇ ¿©·¯ ´Ü°è¿¡µµ °ü¿©ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium-channel blocker
    Ä®½·Åë·ÎÂ÷´ÜÁ¦
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • blocking agent
    Â÷´ÜÁ¦
  • blocking antibody
    Â÷´ÜÇ×ü
  • blocking of thought
    »ç°íµÎÀý
  • cholinergic blocking agent
    Äݸ°Â÷´ÜÁ¦
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • coronary calcium scan
    °ü»óµ¿¸ÆÄ®½·½ºÄµ
  • calcium
    Ä®½·
  • calcium chloride
    ¿°È­Ä®½·
  • calcium ethylenediaminetetraacetic acid
    Ä®½·¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
  • calcium gluconate
    ±Û·çÄÜ»êÄ®½·
  • calcium oxalate stone
    ¼ö»êÄ®½·µ¹
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • channel
    Åë·Î
  • sodium channel
    ³ªÆ®·ýÅë·Î
  • blocking agent
    Â÷´ÜÁ¦
  • blocking antibody
    Â÷´ÜÇ×ü
  • calcium ethylenediaminetetraacetic acid
    Ä®½·¿¡Æ¿·»µð¾Æ¹Î»ç¾Æ¼¼Æ®»ê
  • calcium
    Ä®½·
  • calcium gluconate
    ±Û·çÄÜ»êÄ®½·
  • blocking of thought
    »ç°íµÎÀý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium
    Ä®½·
  • calcium chloride
    ¿°È­Ä®½·
  • calcium oxalate stone
    ¼ö»êÄ®½·µ¹
  • calcium phosphate stone
    ÀλêÄ®½·µ¹
  • calcium-catalyzed reaction
    Ä®½·Ã˸ŹÝÀÀ
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´ÜÁ¦
  • blocking agent
    Â÷´ÜÁ¦
  • blocking antibody
    Â÷´ÜÇ×ü
  • cholinergic blocking agent
    Äݸ°Â÷´ÜÁ¦
  • ganglionic blocking agent
    ½Å°æÀýÂ÷´ÜÁ¦
  • blocking test
    Â÷´Ü½ÃÇè
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø½Å°æ±ÙÂ÷´ÜÁ¦
  • ganglionic blocking drug
    ½Å°æÀýÂ÷´Ü¾àÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • H2 recepor blocking agents, for ulcers
    H2¼ö¿ëüÂ÷´ÜÁ¦(â¥é»ô÷ó´Ó¨ð¥)
  • Chemosensitizing agents
    È­ÇÐÀû °¨°¢Á¦
  • health care agents
    °Ç°­°ü¸®¿ä¿ø(ÊÙËíËô), °Ç°­°ü¸®±â±¸.
  • immunosuppressive agents
    ¸é¿ª¾ïÁ¦ÀÎÀÚ(¡­åäð¤ì×í­)
  • Fast channel
    ±Þ¼Ó(ÐááÜ)Åë·Î(÷×ÖØ)
  • T-type channel
    T-Çü Åë·Î
  • acetylcholine channel
    ¾Æ¼¼Æ¿Äݸ° Åë·Î
  • hepatocardiac channel
    °£½ÉÀå__ÊÜãýíôϵ).
  • porin channel
    Æ÷¸°Åë·Î
  • potassium channel
    Ä®·ýÅë·Î
  • pyloric channel
    À¯¹®Åë·Î.
  • Ganglionic blocking drugs
    ½Å°æÀýÂ÷´Ü¾àÁ¦(ãêÌèï½ó´Ó¨å·ð¥)
  • alpha blocking
    ¾ËÆÄÂ÷´Ü
  • antibody, blocking
    Â÷´ÜÇ×ü
  • ganglionic blocking action
    ½Å°æÀýÂ÷´ÜÀÛ¿ë.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à ¹°<Á¦>, Ä®½·Åë·Î Â÷´Ü¾à¹°<Á¦>.
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • calcium channel
    Ä®½·Åë·Î( -÷×ÖØ).
  • calcium channel
    Ä®½· Åë·Î(÷×ÖØ)
  • calcium channel antagonist,blocker
    Ä®½·Åë·Î ±æÇ×Á¦( -÷×ÖØ ÑÏù÷ð¥),Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • biologic agents
    »ý¹°ÇÐÀûÁ¦Á¦
  • eaton agents
    ÀÌÆ° º´¿øÃ¼
  • health care agents
    °Ç°­°ü¸®¿ä¿ø(ÊÙËíËô), °Ç°­°ü¸®±â±¸.
  • immunosuppressive agents
    ¸é¿ª¾ïÁ¦ÀÎÀÚ(¡­åäð¤ì×í­)
  • law for control of poisonous and powerful agents
    µ¶±Ø¹°Ãëü¹ý(ËÄË»ËŅ̬̃ ËÑ).
  • oral hypoglycemic agents
    °æ±¸´ç´¢º´¾àÁ¦(ÌèÏ¢ÓØèñÜ»å·ð¥).
  • oral hypoglycemic agents
    °æ±¸´ç´¢º´¾àÁ¦(ÌèÏ¢ÓØèñÜ»å·ð¥).
  • proteolytic agents
    ´Ü¹éºÐÇØÁ¦(¡­ÝÂú°ð¥).
  • skin protective agents
    ÇǺκ¸È£Á¦.
  • skin test agents
    ÇǺιÝÀÀ¾à(ù«Ý±Úãëëå·).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium folinate
    Ä®½·Æú¸®³×ÀÌÆ®
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • psychotropic agents
    Á¤½ÅÀÛ¿ë¾à(ïñãêíÂéÄå·)
  • blocking antibody
    Â÷´ÜÇ×ü(ó´Ó¨ù÷ô÷)
  • blocking group
    Â÷´Ü±â(ó´Ó¨Ðñ)
  • channel
    "ä³Î, Åë·Î(÷×ÖØ)"
  • channel protein
    ä³Î ´Ü¹éÁú(Ó±ÛÜòõ)
  • gated channel
    °ü¹® Åë·Î (μڦ÷×ÖØ)
  • ion channel
    À̿ Åë·Î(÷×ÖØ)
  • ligand-gated channel
    ¸®°£µå °ü¹®Åë·Î(μڦ÷×ÖØ)
  • voltage-gated channel
    Àü¾Ð°³Æó(ï³äâËÒøÍ) Åë·Î(÷×ÖØ)
  • calcium
    Ä®½·
  • calcium-activated factor
    Ä®½·ºÎȰ ÀÎÀÚ(Ý·üÀì×í­)
  • calcium-activated neutral proteinase
    Ä®½·ºÎȰ(Ý·üÀ) Áß¼º(ñéàõ)ÇÁ·ÎƼ³×À̽º
  • calcium chloride transformation
    ¿°È­Ä®½· º¯Çü¼ú(ܨû¡âú)
  • calcium-dependent proteinase
    Ä®½·ÀÇÁ¸(ëîðí) ÇÁ·ÎƼ³×À̽º
  • calcium-dependent regulatory protein
    Ä®½·ÀÇÁ¸ Á¶Àý´Ü¹éÁú(ëîðíðàï½Ó±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • calcium
    Ä®½·
  • calcium, milk
    Ä®½·¿ìÀ¯
  • milk of calcium
    ¿ìÀ¯ÇüÄ®½·
  • milk of calcium bile
    ¿ìÀ¯ÇüÄ®½·´ãÁó
  • channel
    Åë·Î
  • collateral channel
    °çÅë·Î, ºÎÇà·Î
  • hepatocardiac channel
    °£½ÉÀ屸
  • lymph channel
    ¸²ÇÁ°ü
  • parallel channel sign
    ÆòÇà°ü¡ÈÄ
  • signal channel
    ½ÅÈ£Åë·Î
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NMB neuromedin B; neuromuscular blockade; neuromuscular blocking; neuromuscular blocker/blocking [drug, ...
SBF serologic-blocking factor; specific blocking factor; splanchnic blood flow
Ca2+-blocker calcium channel blocker
CCB calcium channel blocker
DHPCCB dihydropyridine calcium channel blocker
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
KATP channel ATP sensitive potassium channel
BK channel K channel
CRC Calcium Release Channel
CCA Calcium channel antagonists
CCB Calcium channel blocker
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
  • channel tray ºÐÇÒ º¹À§½Ä ¸ðÇüÀ» Á¦ÀÛÇÒ ¶§ »ç¿ëµÇ´Â ÇÃ¶ó½ºÆ½ ʹÝ. Dilok tray¿Í °°Àº ±â´ÉÀ» ÇÏ´Â °ÍÀÌ´Ù.

    channel-shoulder-pin attachment

    ¾¾ ¿¡½º ÇÇ ºÎ°¡ ÀåÄ¡
    Ä¡°ú ±â°ø½Ç¿¡¼­ Á¦ÀÛÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î °¢Á¾ Àΰø Ä¡°ú
  • calcium channel
    Ä®½· ä³Î
    Ä®½·ÀÌ Åë°úÇÏ´Â µµ°ü.
  • calcium channel blocker
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°, Ä®½· ä³Î Â÷´ÜÁ¦
    µ¿ÀǾî=calcium channel blocking drug. 1. Ä®½·ÀÌ Åë°úÇÏ ´Â µµ°üÀ» ¸·´Â ¾à¹°. 2. Ç× Çù½ÉÁõ Á¦Á¦, Ç×°íÇ÷¾Ð Á¦Á¦, Ç× ºÎÁ¤¸Æ Á¦Á¦·Î »ç¿ëµÇ´Â ¾à¹°·Î½á, µ¿¸ÆÀÇ ÆòȰ±Ù¿¡¼­ Ä®½·ÀÇ À¯ÀÔÀ» Â÷´ÜÇÔÀ¸·Î½á ¸»ÃÊ ¼Òµ¿¸ÆÀ» ÀÌ¿ÏÇØ¼­ ½É±ÙÀÇ »ê¼Ò ¿ä±¸·®À» ÀúÇϽÃŰ´Â ±â´ÉÀ» ÇÑ´Ù. ´ëÇ¥ÀûÀÎ ¾à¹°·Î´Â, vera
  • calcium-channel blocker
    Ä®½· Â÷´ÜÁ¦, Ä®½· Åë·Î Â÷´ÜÁ¦
  • channel block
    Åë·Î Â÷´Ü
  • collateral channel
    °çÅë·Î, ºÎÇà·Î
  • ion channel
    À̿ Åë·Î
    ¼¼Æ÷¸· µî¿¡ Á¸ÀçÇϸç ÀÚ±ØÀÌ ¿À¸é Åë·Î¸¦ ¿­°í, ´ÝÀ½À¸·Î ÇØ¼­ ÀÌ¿ÂÀÇ ³óµµ¸¦ Á¶ÀýÇØ¼­ ÀÚ±ØÀÇ Àü´Þ¿¡ °ü¿©ÇÑ´Ù.
  • parallel channel sign
    ÆòÇà°ü ¡ÈÄ
  • sear channel teeth
    ½Ã¾î ä³Î µµÄ¡
    ºñÇØºÎÇÐÀû ÇüÅÂÀÇ µµÄ¡·Î¼­ ±³ÇÕ¸éÀº »ó, ÇÏ¾Ç ¸ðµÎ °ÅÀÇ ÆòźÇϰí ÇϾǿ¡¼­´Â ±Ù¿ø½ÉÀûÀ¸·Î ´Þ¸®´Â °¡´Â µ¹±â°¡ ÀÖÀ¸¸ç »ó¾Ç¿¡´Â À̰ÍÀÌ µé¾î°¡´Â ¾èÀº ±¸°¡ ÀÖ´Ù.
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸° Â÷´ÜÁ¦
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¿¡ ÀÛ¿ëÇÏ¿© ½Å°æ Àü´Þü¿Í ¼ö¿ëü°¡ °áÇÕÇÏÁö ¸øÇÏ°Ô ÇÔÀ¸·Î½á ±³°¨½Å°æ ÈïºÐ È¿°ú¸¦ ºÀ¼âÇÏ´Â ¾à¹°.
  • autonomic blocking agent
    ÀÚÀ² ½Å°æ Â÷´ÜÁ¦
  • beta-adrenergic blocking agent
    º£Å¸ ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • blocking
    Â÷´Ü, ºÀ¼â, Â÷´Ü¾à, ºÀ¼â¾à, Á¡Âø
    1. ±¸½É¼º ½Å°æ·ÎÀÇ Â÷´Ü, ¿¹ÄÁµ¥ ÄÚÄÉÀÎ ÁÖ»ç·Î ÀÎÇÑ Â÷´Ü. ¼¼Æ÷³» »ýÇÕ¼º °úÁ¤ÀÇ ÀúÁö. 2. ¾î¶² ÄÞÇ÷º½º¿¡ ºÎµúÃÆÀ» ¶§ °©ÀÛ½º·± ¿¬»óÀÇ Á¤Áö¿¡ ´ëÇÑ ÇÁ·ÎÀ̵åÇÐÆÄÀÇ ¿ë¾î. 3. ¼¿·ÎÀ̵òÀ¸·Î ħÅõ½ÃŲ Á¶Á÷ Ç¥º»À» ¸ñÆíÀ̳ª ±âŸ ´Ù¸¥ Àû´çÇÑ ¹°Áú·Î °íÁ¤½ÃÄÑ ¸¶ÀÌÅ©·ÎÅè¿¡ ºÎÂø½Ãų ¼ö ÀÖ°Ô ÇÏ´Â °Í.
  • blocking antibody
    Â÷´Ü Ç×ü
    µ¿ÀǾî=blocker.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
slow channel-blocking agent calcium channel-blocking agent
spermatogenesis-blocking agents Chemical substances which inhibit the process of spermatozoa formation at either the first stage, in which spermatogonia develop into spermatocytes and then into spermatids, or the second stage, in which spermatids transform into spermatozoa.
(12 Dec 1998)
neuromuscular blocking agents Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarising agents) or noncompetitive, depolarising agents (neuromuscular depolarising agents). Both prevent acetylcholine from triggering the muscle contraction and they are used as anaesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.
(12 Dec 1998)
calcium channel <physiology> A membrane channel that is specific for calcium. It is a voltage-dependent cell membrane glycoproteins selectively permeable to calcium ions. They are categorised as l, t, n, or p types based on the activation and inactivation kinetics, ion specificity, and sensitivity to drugs and toxins.
(12 May 2002)
calcium channel agonist <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues.
This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture.
(12 Dec 1998)
calcium channel antagonist <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
calcium channel-blocker <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
ryanodine receptor calcium release channel Protein complexes that mediate the release of calcium from the sarcoplasmic reticulum in both skeletal and cardiac muscle cells by forming tetrametric complexes. These complexes each then act as a calcium channel. There are three isoforms of the ryr: ryr1, ryr2, and ryr3. Ryr1 is specifically expressed in skeletal muscles and ryr2 in cardiac muscles. Ryr3 is yet another isoform found in non-muscle cells such as neuronal cells.
(12 Dec 1998)
adrenergic blocking agent A compound that selectively blocks or inhibits responses to sympathetic adrenergic nerve activity (sympatholytic agent) and to epinephrine, norepinephrine, and other adrenergic amines (adrenolytic agent); two distinct classes exist, alpha-and beta-adrenergic receptor blocking agent's.
(05 Mar 2000)
adrenergic neuronal blocking agent A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines.
(05 Mar 2000)
alpha-adrenergic blocking agent An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension.
Synonym: alpha-blocker.
(05 Mar 2000)
alpha blocking The attenuation of the occipital alpha rhythm (8-14 Hz brain waves as seen on an electroencephalogram), produced by opening the eyes or by intense mental concentration.
(05 Mar 2000)
antibodies, blocking Antibodies that inhibit the reaction between antigen and other antibodies or sensitised T-lymphocytes (e.g., antibodies of the IgG class that compete with IgE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumours and prevent destruction of tumour cells by cytotoxic T-lymphocytes have also been called enhancing antibodies.
(12 Dec 1998)
beta-adrenergic blocking agent A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
beta-adrenergic receptor blocking agent A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blocking
    ¿À¸®´ë(Æ´À» ¸Þ¿ì´Â ³ª¹µÁ¶°¢);ºí·ÎÅ·;ÀúÁö Çö»ó(¹Ù¶÷Á÷ÇÏÁö ¾ÊÀº »ó³ä¿¡ ÀÇÇÑ ¿¬»ó Áß´Ü);(¹è¿ìÀÇ)¿¬Ãâ;ºí·ÎÅ·Çϱâ
  • calcium
    Ä®½·
  • calcium
    Ä®½·(±Ý¼Ó¿ø¼Ò,±âÈ£ Ca,¹øÈ£ 20)
  • calcium arsenate
    ºñ»êÄ®½·(»ìÃæÁ¦)
  • calcium carbide
    źȭĮ½·
  • calcium carbonate
    ź»êÄ®½·
  • calcium chloride
    ¿°È­Ä®½·
  • calcium hydroxide
    ¼ö»êÈ­Ä®½·;¼Ò¼®È¸
  • calcium light
    Ä®½·±¤(limelight)
  • calcium oxide
    »êÈ­Ä®½·;»ý¼®È¸
  • calcium phosphate
    ÀλêÄ®½·
  • channel
    ¼ö·Î
  • Channel Islands
    ÇØÇùÁ¦µµ(ÇÁ¶û½º ºÏ¼­ºÎÀÇ ¿µ·ÉÀÇ ¼¶)
  • English Channel
    ¿µ±¹ ÇØÇù
  • North Channel
    ³ë½º ÇØÇùÄÚÆ²·£µå¿Í ºÏ¾ÆÀÏ·£µå »çÀÌ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á